



Alberta Public Health Disease Management Guidelines

Chlamydia



This publication is issued under the Open Government Licence – Alberta (<http://open.alberta.ca/licence>). Please note that the terms of this licence do not apply to any third-party materials included in this publication.

This publication is available online at <https://open.alberta.ca/publications/chlamydia>

For further information on the use of this guideline contact:

Health.CD@gov.ab.ca

Health and Wellness Promotion Branch

Public Health and Compliance Branch

Alberta Health

Chlamydia | Alberta Health, Government of Alberta

© 2021 Government of Alberta | October 2021

Table of Contents

Revision History	4
Case Definition	5
Confirmed Case	5
Reporting Requirements	6
Physicians, Health Practitioners and Others	6
Laboratories.....	6
Alberta Health Services - STICS.....	6
Additional Reporting Requirements for Physicians, Health Practitioners and Others	7
Clinical Presentation and Epidemiology	8
Etiology	8
Clinical Presentation.....	8
Diagnosis.....	9
Treatment.....	9
Reservoir.....	9
Transmission.....	10
Incubation Period	10
Period of Communicability	10
Host Susceptibility	10
Incidence	10
Public Health Management	11
Key Investigation	11
Management of a Case.....	11
Management of Contacts	12
Preventive Measures	13
Screening	13
References.....	14

Revision History

Revision Date	Document Section	Description of Revision
October 2021	General	<ul style="list-style-type: none">• Updated Template• Diagnosis and Treatment section moved to Epidemiology• Updated web links
	Incidence	<ul style="list-style-type: none">• Removed graphs as outdated

Case Definition

Confirmed Case

Footnote ^(A) applies to this section.

Genital and Extra-Genital Infections

Laboratory evidence of *Chlamydia trachomatis* infection in genitourinary specimens^(B) (e.g., endocervical, urethral, penile, or vaginal swab; urine) and/or rectum, conjunctiva, pharynx, or other extra-genital sites from appropriate specimen:

- Molecular detection of *C. trachomatis* (e.g., Nucleic Acid Amplification Testing [NAAT])

Perinatally Acquired Infections

Laboratory evidence of *C. trachomatis* infection in nasopharyngeal or other respiratory tract specimens (e.g., nasopharyngeal swab, auger suction, tracheal aspirates, throat swab) or in urine from an infant who developed pneumonia in the first six months of life:

- Molecular detection of *C. trachomatis* (e.g., NAAT)

OR

Laboratory evidence of *C. trachomatis* in conjunctival specimens from an infant who developed conjunctivitis in the first month of life:

- Molecular detection of *C. trachomatis* (e.g., NAAT)

^(A) Each case classification is mutually exclusive. Individuals with more than one site of infection concurrently may fall under more than one case classification but will be counted as one case with multiple sites of infection identified to avoid duplicate counting of cases.

^(B) Refer to the [Public Health Laboratory \(ProvLab\) Guide to Services](#) for current specimen collection and submission information.

Reporting Requirements

Physicians, Health Practitioners and Others

Note: This section includes First Nations and Inuit Health Branch

Physicians, health practitioners and others shall notify the Sexually Transmitted Infection (STI) Medical Director^(C) via Sexually Transmitted Infection Centralized Services (STICS), of all confirmed cases within 48 hours (two business days) by forwarding a completed [Notification of STI](#) form.

Laboratories

- All laboratories shall report all positive laboratory results by mail, fax or electronic transfer within 48 hours (two business days) to the STI Medical director via STICS and the Chief Medical Officer of Health (CMOH) (or designate).

Alberta Health Services - STICS

Contact Information:

Toll free: 1-855-945-6700 option 4

Fax: 780-670-3624

The STI Medical Director/STICS shall forward the initial Notification of STI form of all confirmed cases to the CMOH (or designate) within two weeks of notification and the final Notification of STI form within four weeks. The STI Medical Director/STICS are responsible for ensuring investigation and follow-up of all reported confirmed cases.

- The STI Medical Director/STICS shall forward the [Perinately Acquired Notifiable Disease Enhanced Report](#) form for all confirmed and probable cases of perinately acquired disease to the CMOH (or designate) within four weeks of notification.
- For out-of-province and out-of-country reports, the following information (when available) should be forwarded to the CMOH (or designate) by phone, fax or secure/encrypted electronic transfer as soon as possible:
 - name,
 - date of birth,
 - out-of-province health care number,
 - out-of-province address and phone number,
 - positive laboratory report, and
 - other relevant clinical/epidemiological information.
- For out-of-province and out-of-country contacts the following information (when available) should be forwarded to the CMOH (or designate) as soon as possible:
 - name,

^(C) The STI Medical Director is the Provincial Medical Director of Alberta Health Services' Sexually Transmitted Infection Centralized Services (STICS) and is also a Medical Officer of Health.

- date of birth,
- date of exposure, and
- out-of-province/country contact information.

Additional Reporting Requirements for Physicians, Health Practitioners and Others

In all cases, where a person under 18 is suspected or confirmed to have a STI, an assessment should be carried out by the clinician to determine if additional reporting is required.

To Alberta Child and Family Services

- The clinician should determine whether there are reasonable and probable grounds to believe that they are in contact with “a child in need of intervention” (as per Section 1(2) of the [Child, Youth and Family Enhancement \(CYFE\) Act](#)) and shall report to a director pursuant to Section 4 of the *CYFE Act*.⁽¹⁾
- Reporting is done by contacting the local Child and Family Services office or calling the **CHILD ABUSE HOTLINE: 1-800-387-5437 (KIDS)**. For local office contact information see [the ministry’s website](#).

To Law Enforcement Agency

- Consent is a key factor in determining whether any form of sexual activity is a criminal offence. Children under 12 do not have the legal capacity to consent to any form of sexual activity. The law recognizes that the age of consent for sexual activity is 16. However, the law identifies the exception for minors between 12 and 16 years as having the ability to consent, in “close in age” or “peer group” situations.⁽²⁾
- Reporting is done by contacting your local City Police Detachment or [RCMP Detachment](#).
- For additional information:
 - Alberta [Child, Youth and Family Enhancement Act](#)
 - Age of Consent to Sexual Activity at www.justice.gc.ca/eng/rp-pr/other-autre/clp/faq.html
 - Criminal Code of Canada at www.laws-lois.justice.gc.ca/eng/acts/C-46/⁽³⁾

Clinical Presentation and Epidemiology

Etiology

Chlamydia trachomatis is a bacterial agent (obligate intracellular parasite). Genital, extra-genital, and perinatal infections are generally caused by serovars A through K.⁽⁴⁾

Clinical Presentation

Genital Infections

Symptomatic and asymptomatic genital chlamydial infections occur, but the majority of infections are asymptomatic. Males are more likely to have symptoms than females. When symptoms occur, the spectrum of clinical manifestations is varied.

Symptomatic genital infection in males is generally characterized by urethritis including urethral discharge, dysuria and frequency, and non-specific symptoms such as redness, itch and swelling of the urethra. These symptoms, if untreated, can lead to complications including epididymitis, Reiter's Syndrome (oligoarthritis) and occasionally infertility.

Symptomatic females will most often experience cervical or vaginal discharge, dysuria and frequency, painful intercourse, lower abdominal pain, abnormal bleeding between periods, and vaginal symptoms including redness, itch and swelling. If untreated, complications such as ectopic pregnancy, infertility, pelvic inflammatory disease (PID) (e.g., oophoritis, endometritis, salpingitis), and rarely Reiter's syndrome may occur. Up to 2/3 of cases of tubal-factor infertility and 1/3 of cases of ectopic pregnancy may be attributed to *C. trachomatis* infection.⁽⁴⁻⁶⁾

Extra-Genital Infections

Pharyngeal and rectal infections are often asymptomatic. Rectal symptoms, when present, include rectal pain (proctitis or proctocolitis), mucoid discharge, blood in the stool and tenesmus.⁽⁴⁾

Conjunctivitis in adults manifests with preauricular lymphadenopathy, hyperemia, infiltration and mucopurulent discharge. There may also be a chronic phase with discharge and symptoms which may last for a year or longer if untreated.⁽⁶⁾

Perinatally Acquired Infections

Conjunctivitis symptoms usually appear between seven and 21 days post-natally, often starting as a mucoid discharge and progressing to a more purulent discharge. The eyelids become edematous and the conjunctiva becomes erythematous and thick. Symptoms of infant pneumonia include staccato cough, dyspnea, and a low-grade fever. Infants usually become symptomatic between 10 days and five months of age.⁽⁷⁾

Diagnosis

Diagnosis is made based on history, physical examination, and laboratory investigation. The diagnosis is confirmed by examination of genitourinary, rectal, pharyngeal, or conjunctival samples by molecular diagnostic tests.

In infants under six months of age, the specimen is generally taken from the nasopharynx or the respiratory tract. The organisms are less easily recovered from discharge.

Treatment

Indications for treatment are:

- positive diagnostic test result,
- diagnosis of a syndrome compatible with a chlamydial infection, without waiting for test result, and/or
- partner with a positive chlamydia test result or diagnosis of a syndrome compatible with a chlamydial infection in a partner without waiting for test results

Refer to the current [Alberta Treatment Guidelines for STI in Adolescents and Adults](#).

Considerations

- If vomiting occurs more than one hour post administration of azithromycin, a repeat dose is not required.
- Doxycycline is contraindicated in pregnant women.

Pediatric Cases

- When a case is diagnosed in an infant, the mother and her sexual partner(s) should be examined and tested.
- It is recommended that all children < 14 years of age be referred to a pediatrician and, because of the high risk of sexual abuse (excepting those < one month of age with a conjunctivitis or < six months of age with pneumonia), be managed in consultation with one of the following referral centres.

Edmonton

Child and Adolescent Protection Centre
Stollery Children's Hospital
1C4.24 Mackenzie Health Sciences Centre
8440-112 Street
Edmonton, Alberta T6G 2B7
Tel: 780-407-1240

Calgary

Child Abuse Service
Child Development Centre
Suite 200, 3820-24 Ave NW
Calgary, Alberta. T2N 1N4
Tel: 403-955-5959

Reservoir

Humans are the only known reservoir.⁽⁵⁾

Transmission

Transmission of *C. trachomatis* is person-to-person via sexual contact (oral, vaginal, or anal sex), or through the birth process (vertical transmission). The transmission is more efficient male to female than female to male. The bacteria may also spread from the primary site of the case to other sites, causing infection of the uterus, fallopian tubes, ovaries, abdominal cavity, glands of the vulva area in females, and testes in males. The eyes of adults may become infected through the transmission of the infected genital secretions to the eye, typically by the fingers. Newborns become infected by direct contact with an infected birth canal.^(5–7)

Incubation Period

The incubation period is variable depending upon the type/site of infection. It is commonly 7–14 days, but can be as long as six weeks.

Period of Communicability

Chlamydia trachomatis is communicable for as long as the person harbours the organism. This may be for many months in untreated individuals.⁽⁸⁾

Host Susceptibility

All persons are susceptible to this disease if exposed. No acquired immunity has been demonstrated and, in fact, it has been demonstrated that the recurrent infection rate among young sexually active individuals is quite high.

Incidence

Genital chlamydia became reportable in Alberta in 1989. It remains the most frequently reported STI in Alberta, diagnosed more often in females than males.

Refer to the [Interactive Health Data Application](#) for more information.

Public Health Management

Key Investigation

The diagnosis and treatment is performed by community health care providers.

- Determine the presence or absence of symptoms.
- Determine if behaviors that increase risk for chlamydia are present:
 - sexual contact with chlamydia infected person(s),
 - new sexual partner or more than two sexual partners in preceding year,
 - previous STI, and/or
 - vulnerable populations (e.g., injection drug use (IDU), incarcerated individuals, people involved in exchanging goods for sex, street involved youth, etc.).
- Offer testing for HIV and other STI.
- Counsel and identify partners, including locating information.

Management of a Case

- Test of cure for *C. trachomatis* is not routinely recommended for genital infections when treatment according to guidelines is taken, signs and symptoms disappear, and there is no re-exposure to an untreated partner.
- Test of cure is recommended when:
 - compliance is sub-optimal,
 - an alternative treatment regimen has been used,
 - the patient is a child (< 14 years of age),
 - the patient is a pregnant woman,
 - a non-genital site is involved (e.g., eye, rectum, pharynx), and
 - cases involve complicated infection (PID or epididymitis).
- A NAAT is performed three to four weeks after completion of treatment.
- Empirical co-treatment for gonorrhea is recommended in areas of high gonococcal disease prevalence, prior to test results becoming available.
- Repeat testing for all individuals with chlamydia infections is recommended six months post- treatment.
- All cases should be instructed about infection transmission. Patients should be counseled about the importance of abstaining from unprotected intercourse until seven days after completion of treatment by both case and partner(s).
- All cases should be provided with individualized STI prevention education, targeted at developing knowledge, skills, attitudes and behaviors to reduce the risk and prevent recurrences of STI.
- Immunization against hepatitis A, B, and HPV may be recommended. Refer to the [Alberta Immunization Policy](#) for immunization eligibility.
- All patients with a notifiable STI qualify for provincially funded medications.

- STICS will send replacement medication upon receipt of a Notification of STI Form when the health care provider mailing address is indicated on the form.
- Health care providers may order additional quantities of most medications by contacting STICS.

To obtain the phone number for your designated **Partner Notification Nurse**, or for advice on management of your case, call **STICS Toll free: 1-855-945-6700 option 4**

- Sexual assault in adults should be managed in conjunction with local Sexual Assault services and other appropriate community support services.

Recalcitrant Patients

The [Public Health Act](#) (sections 39 through 52) authorizes detention of recalcitrant patients for medical examination, treatment and/or counselling.

- The CMOH (or designate) or MOH (or designate) may issue a certificate to detain an individual who is believed to be infected and refuses or neglects to comply with treatment.
- In order to enact this provision, there must be proof of infection or contact with an infected person and:
 - documentation of failure to comply with prescribed treatment and medical examination, or
 - non-compliance for testing and/or treatment.

Management of Contacts

Partner Notification

- Partner notification will identify those at risk, reduce disease transmission/re-infection and ultimately prevent disease sequelae.
- **It is mandated under the *Communicable Disease Regulation* that every attempt is made to identify, locate, examine and treat partners/contacts of all cases.**
- All contacts should be:
 - screened for HIV and other STI,
 - instructed about infection transmission, and
 - provided with individualized STI prevention education targeted at developing knowledge, skills, attitudes and behaviors to reduce the risk and prevent recurrences of STI.
- Health care providers are required to provide partner names and locating information on the Notification of STI form and forward to STICS.
- If testing and/or treatment of partner(s) are not confirmed on the Notification of STI form, STICS will initiate follow up by a Partner Notification Nurse (PNN).
 - PNNs are specially trained to conduct notification of partners and contacts in a confidential manner that protects the identity of the index case.

The phone number for your designated PNN is available by calling **STICS Toll free: 1-855-945-6700 option 4**.

- STICS will follow-up on any incoming referrals of cases and partner(s) from all out of province/country referrals.

Preventive Measures

- Ensure appropriate treatment of *C. trachomatis* for cases.
- Interview the case, identify and ensure appropriate treatment and follow-up of *C. trachomatis* for sexual partner(s).
- Ensure STI care is culturally appropriate, inclusive, readily accessible, and acceptable.
- Include information about risk for STI during pre-travel health counseling.
- Educate the case, sexual partners, and the public on methods of personal protective measures, in particular the correct and consistent use of condoms and discuss safer sex options including:
 - delaying onset of sexual activity,
 - developing mutually monogamous relationships,
 - reducing the numbers of sexual partners, and
 - discouraging behaviors associated with the acquisition and transmission of STI.

Screening

- Individuals with risk factors for chlamydia infections:
 - sexual contact with chlamydia infected person(s),
 - new sexual partner or more than two sexual partners in preceding year,
 - previous STI, and
 - vulnerable populations (e.g., IDU, incarcerated individuals, those who exchange goods/money for sex, and street involved youth).
- All sexually active persons under 25 years of age, at least annually.
- All pregnant women. See [Alberta Prenatal Screening Guidelines for Select Communicable Diseases](#).
- Women prior to insertion of an IUD, a therapeutic abortion, or a dilation and curettage.
- Victims of sexual assault.

References

1. Department of J. Child Youth and Family Enhancement Act Policy Manual. Government of Alberta. Government of Alberta; 2010.
2. Government of Canada. Age of Consent to Sexual Activity [Internet]. Ottawa: Government of Canada; 2011. Available from: <http://www.justice.gc.ca/eng/dept-min/clp/faq.html>
3. Department of Justice. Criminal Code of Canada. Government of Canada. Government of Canada; 2011.
4. Zenilman, Jonathan, Shahmanesh M. Sexually Transmitted Infections. In: 1st ed. Sudbury: Jones and Bartlett Learning; 2012. p. 464.
5. Gorwitz, r., Torrone, E., Ndowa F. Control of Communicable Diseases Manual. In: Heymann D, editor. 20th ed. Washington D.C.: American Public Health Association; 2015. p. 99–101.
6. Chan PA, Janvier M, Alexander NE, Kojic EM, Chapin K. Recommendations for the diagnosis of *Neisseria gonorrhoeae* and *Chlamydia trachomatis*, including extra-genital sites. *Med Health R I* [Internet]. 2012;95:252–4. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3763711&tool=pmcentrez&rendertype=abstract4>
7. American Academy of Pediatrics. Red Book: 2018 Report of the committee of Infectious Diseases. 31st ed. DW Kimberlin, MT Brady, MA Jackson SL, editor. Itasca: American Academy of Pediatrics; 2018. 5
8. Government of Canada. Canadian Guidelines on Sexually Transmitted Infections [Internet]. 2018. Available from: www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/sexually-transmitted-infections.html 6